CAI Company Profile and Key Details

CAI has shown mixed momentum, gaining 2.62% over the past week and -16.6% over the past quarter, though year-to-date performance is down -2.63%. Short-term trend indicators are bullishly aligned (SMA20 -9.0%, SMA50 -22.14%, SMA200 -32.53%). The stock’s 14-day RSI is 34.48 (weak momentum), while the ATR of 1.28 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -54.73% below its high and over 12.19% above its low. Average 10-day trading volume of 3.63 million shares is slightly above the 3-month average of 3.23 million, indicating heightened recent market interest.

Caris Life Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$15.87. This means the shares are trading below this model’s fair value.

Caris Life Sciences, Inc. has 282.68 million shares outstanding. The public float is 103.28 million shares, elevated short interest at 10.18% of float. This equals 11.73 million shares. The short ratio is 3.52 days. Institutional investors hold 110.39% of the float. Insiders own 48.51%. HALBERT JON holds 704.60 thousand shares, Spetzler David Baxley has 460.78 thousand shares and Power Luke Thomas has 99.57 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Caris Life Sciences, Inc. (NASDAQ:CAI) closed at $16.09 USD, gaining $0.50 (3.21%) from the previous close of $15.59. The stock is currently mid-range between its 52-week high and low $14.19 and $42.50. With a market capitalization of about $4.55 billion, Caris Life Sciences, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.59). Key stats such as the average daily volume over the past year has been around 3.25 million shares, in line with its 52-week average. Headquartered in Irving, TX, Caris Life Sciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Dean Halbert, the company employs approximately 1,846 people and listed since June 18, 2025. Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally.

Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 7 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $21.00. The high target offers 179.68% upside. The low target suggests 30.52% downside. The mean target is $31.17. This offers 93.72% upside. Caris Life Sciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -1550.0%. The prior quarter beat by -1500.0%. Over the last six quarters, Apple has recorded several small beats. These include 157.14% in August 12, 2025.

Caris Life Sciences, Inc. trades at a P/E ratio of -10.17, slightly below the S&P 500 average, with a price-to-sales ratio of 4.93 and a price-to-book ratio of 7.53 trading at moderately above to book value. The P/FCF stands at 36.23, also above market averages.

Caris Life Sciences, Inc. (NASDAQ:CAI) shares are flat -2.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Caris Life Sciences, Inc. trading at a premium to the broader market with a P/E of -10.17. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $31.46, suggesting 95.53% upside. Our AI forecast model points to short-term weakness (-13.11% over two weeks), a medium-term fall (-3.85% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Caris Life Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.11%, with price expected at $13.98 by August 12, 2026, within a range of $13.50 to $14.48 3-Month Outlook: Projected fall of -3.85%, reaching $15.47 by October 27, 2026, with a range of $15.01 to $15.90. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by July 29, 2027, within a range of $0.00 to $0.00.